Proliferative vitreoretinopathy: An overview

Survey of Ophthalmology

Volumn 43, Issue 1, 1998, Pages 3-18

  Pastor, J Carlos ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Extracellular matrix; Growth factors; Inflammation; Proliferative vitreoretinopathy; Retinal detachment; Wound healing

Indexed keywords

CARMUSTINE; COLCHICINE; CORTICOSTEROID; CYTOKINE; DAUNORUBICIN; DEXAMETHASONE; FLUOROCARBON; FLUOROURACIL; GAMMA INTERFERON; HEPARIN; INTERLEUKIN 4; LOW MOLECULAR WEIGHT HEPARIN; NILVADIPINE; PACLITAXEL; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; RETINOIC ACID; RETINOL; SILICONE OIL; SURAMIN; TRAPIDIL; TRIAMCINOLONE ACETONIDE;

ANIMAL MODEL; CORTICOSTEROID THERAPY; DRUG DELIVERY SYSTEM; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA DETACHMENT; RETINOPATHY; RETINOTOMY; REVIEW; SUBCONJUNCTIVAL DRUG ADMINISTRATION; VITREORETINOPATHY; WOUND HEALING;

ANIMALS; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; HUMANS; RETINAL DETACHMENT; RISK FACTORS; VITREORETINOPATHY, PROLIFERATIVE; WOUND HEALING;

EID: 0032128359     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(98)00023-X     Document Type: Review

References (139)

1. Abrams G., Glazer L. Proliferative vitreoretinopathy. Freeman W.R. Practical Atlas of Retinal Disease and Therapy. 1993;279-297 Raven Press Ltd, New York.
2. Aguirrebeña A., Saornil M.A., Giraldo A., Pastor J.C. Incidencia de la vitreorretinopatía proliferante (VRP) en el desprendimiento de retina regmatógeno. Arch Soc Esp Oftalmol. 51:1986;229-234.
3. Algvere P.V., Gjotterberg M., Olivestedt G., Fituri S. Results of pneumatic retinopexy with air. Acta Ophthalmol. 70:1992;632-636.
4. Alturki W., Peyman G., Paris C.et al. Posterior relaxing retinotomies. Analysis of anatomic and visual results Ophthalmic Surg. 23:1992;685-688.
5. Araiz J.J., Refojo M.F., Arroyo M.et al. Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 34:1993;522-530.
6. Arroyo M., Refojo M.F., Araiz J.J.et al. Silicone oil as a delivery vehicle for BCNU in rabbit proliferative vitreoretinopathy. Retina. 13:1993;245-250.
7. Baudouin C., Brignole F., Bayle J.et al. Class II histocompatibility antigen expression by cellular components of vitreous and subretinal fluid in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 32:1991;2065-2072.
8. Baudouin C., Fredj-Reygrobellet D., Gordon W.C.et al. Immunohistologic study of epiretinal membranes in proliferative vitreoretinopathy. Am J Ophthalmol. 110:1990;593-598.
9. Berger A., Cheng C.K., Pearson P.A.et al. Intravitreal sustained release corticosteroid-5-fluorouracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 37:1996;2318-2325.
10. Berman D.H., Gombos G.M. Proliferative vitreoretinopathy. does low-dose colchicine have an inhibitory effect? A controlled study in humans Ophthalmic Surg. 20:1989;268-272.
11. Binder S., Bonnet M., Velikay M.et al. Radiation therapy in proliferative vitreoretinopathy. A prospective randomized study. Graefes Arch Clin Exp Ophthalmol. 232:1994;211-214.
12. Blumenkranz M.S., Azen S.P., Aaberg T.et al. Relaxing retinotomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy. Silicone Study Report 5. Am J Ophthalmol. 116:1993;557-564.
13. Blumenkranz M.S., Hernandez E., Ophir A., Norton E.W.D. 5-Fluorouracil. new applications in complicated retinal detachment for an established antimetabolite Ophthalmology. 91:1984;122-130.
14. Blumenkranz M.S., Ophir A., Claflin A.J., Hajek A. Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol. 94:1982;458-467.
15. Bonnet M. Macular changes and fluorescein angiographic findings after repair of proliferative vitreoretinopathy. Retina. 14:1994;404-410.
16. Bonnet M. Clinical findings associated with the development of postoperative PVR in primary rhegmatogenous retinal detachment. Heimann K., Wiedemann P. Proliferative Vitreoretinopathy. 1989;8-20 Kaden, Heidelberg.
17. Bonnet M. Clinical factors predisposing to massive proliferative vitreoretinopathy in rhegmatogenous retinal detachment. Ophthalmologica (Basel). 188:1984;148-152.
18. Bonnet M., Guenoun S. Surgical risk factors for severe postoperative proliferative vitreoretinopathy (PVR) in retinal detachment with grade B PVR. Graefes Arch Clin Exp Ophthalmol. 233:1995;789-791.
19. Bourke R.D., Cooling R.J. Vascular consequences of retinectomy. Arch Ophthalmol. 114:1996;155-160.
20. Broekhuyse R.M., Rademakes A.J., Van Vugt A.H., Winkens H.J. Autoimmune responsiveness to retinal IRBP, S-antigen and opsin in proliferative vitreoretinopathy. Exp Eye Res. 50:1990;197-202.
21. Campochiaro P.A., Bryan J.A., Conway B.P., Jaccoma E.H. Intravitreal chemotactic and mitogenic activity. Implications of blood-retinal barrier breakdown Arch Ophthalmol. 104:1986;1685-1690.
22. Campochiaro P.A., Glaser B.M. Platelet derived growth factor is chemotactic for human retinal pigmented epithelial cells. Arch Ophthalmol. 103:1985;576-579.
23. Campochiaro P.A., Jerdan J.A., Glaser B.M. Serum contains chemoattractants for human retinal epithelial cells. Arch Ophthalmol. 102:1984;1830-1833.
24. Casaroli R., Vilaró S. The role of fibronectin, laminin, vitronectin and their receptors on cellular adhesion in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 35:1994;2791-2803.
25. Chandler D.B., Hida T., Sheta S.et al. Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. Graefes Arch Clin Exp Ophthalmol. 225:1987;259-265.
26. Chang S. Low viscosity liquid fluorochemicals in vitreous surgery. Am J Ophthalmol. 103:1987;38-43.
27. Chang S., Lincoff H., Zimmerman N.J.et al. Giant retinal tears. Surgical techniques and results using perfluorocarbon liquids Arch Ophthalmol. 107:1989;761-766.
28. Chang S., Zimmermman N.J., Iwamoto T.et al. Experimental vitreous replacement with perfluorotributylamine. Am J Ophthalmol. 103:1987;29-37.
29. Chapman C., Iverson D., Hartzer M.et al. The effect of low-molecular-weight heparin on proliferative vitreoretinopathy induced in the rabbit eye (abstract). Invest Ophthalmol Vis Sci. 33(Suppl):1992;855.
30. Charteris D.G. Proliferative vitreoretinopathy. pathobiology, surgical management, and adjunctive treatment Br J Ophthalmol. 79:1995;953-960.
31. Charteris D.G., Hiscott P., Grieson I., Lightman S. Proliferative vitreoretinopathy. Lymphocytes in epiretinal membranes. Ophthalmology. 99:1992;1364-1367.
32. Charteris D.G., Hiscott P., Robey H.L.et al. Inflammatory cells in proliferative vitreoretinopathy subretinal membranes. Ophthalmology. 100:1993;43-46.
33. Christmas N.J., Skolik S.A., Howard M.A.et al. Treatment of retinal breaks with autologous serum in an experimental model. Ophthalmology. 102:1995;263-271.
34. Coleman D.J., Lucas B.C., Fleischmann J.A.et al. A biologic tissue adhesive for vitreoretinal surgery. Retina. 8:1988;250-256.
35. Cowley M., Conway B.P., Campochiaro P.A.et al. Clinical risk factors for proliferative vitreoretinopathy. Arch Ophthalmol. 107:1989;1147-1151.
36. Daniels S., Coonley K., Yoshizumi M. Taxol treatment of experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 228:1990;513-516.
37. Davis A.A., Whidby D.E., Privette T.et al. Selective inhibition of growing pigment epithelial cells by a receptor-direct immunotoxin. Invest Ophthalmol Vis Sci. 31:1990;2514-2519.
38. De Juan E., McCuen B.W. Management of anterior vitreous in proliferative vitreoretinopathy. Retina. 9:1989;258-261.
39. Diddie K., Azen S., Freeman H.et al. Anterior proliferative vitreoretinopathy in the silicone study. Silicone Study Report Number 10. Ophthalmology. 103:1996;1092-1099.
40. Eckardt C., Behrendt S., Zwick A. Results of silicone oil removal from eyes treated with retinectomies. Ger J Ophthalmol. 1:1992;2-6.
41. Elner S., Elner V.M., Jaffe G.et al. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res. 14:1995;1045-1053.
42. Federman J.L., Eagle R.C. Extensive peripheral retinectomy combined with posterior 360° retinotomy for retinal reattachment in advanced proliferative vitreoretinopathy cases. Ophthalmology. 97:1990;1305-1320.
43. Federman J.L., Schubert H.D. Complications associated with the use of silicone oil in 150 eyes after retina-vitreous surgery. Ophthalmology. 95:1988;870-876.
44. García-Layana A., Gonzalez G., Saornil M.A.et al. Papel del factor de crecimiento derivado de las plaquetas (PDGF) en un modelo experimental de VRP en el cerdo. Arch Soc Esp Oftalmol. 68:1995;123-130.
45. García-Layana A., Hernando M.T., Manzanas L., Pastor J.C. Tratamiento profiláctico de la vitreoretinopatía proliferante. Arch Soc Esp Oftalmol. 60:1991;315-322.
46. García-Layana A., Pastor J.C., Saornil M.A., Gonzalez G. Porcine model of proliferative vitreoretinopathy with platelets. Curr Eye Res. 16:1997;556-563.
47. Gilbert C.E. Adhesives in retinal detachment surgery. Br J Ophthalmol. 75:1991;309-310.
48. Girard P., Mimoun G., Karpouzas I., Montefiore G. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina. 14:1994;417-424.
49. Glaser B.M. Surgery for proliferative vitreoretinopathy. Ryan S.J. Retina. 2:1994;2265-2280 CV Mosby, St Louis.
50. Glaser B.M., Lemor M. Pathobiology of proliferative vitreoretinopathy. Ryan S.J. Retina. 2:1994;2249-2263 CV Mosby, St Louis.
51. 2 for the treatment of full-thickness macular holes. A prospective randomized study. Ophthalmology. 99:1992;1162-1173.
52. Glaser B.M., Vidaurri-Leal J., Michels R., Campochiaro P.A. Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells. Ophthalmology. 100:1993;466-470.
53. Goldaracena M.B., García-Layana A., De la Fuente L.F.et al. Estudio inmunocitoquímico de las membranas perirretinianas en un modelo experimental de vitreoretinopatía proliferante (VRP). Arch Soc Esp Oftalmol. 63:1992;519-524.
54. Goldaracena M.B., García-Layana A., Pastor J.C.et al. The role of retinotomy in an experimental model of proliferative vitreoretinopathy. Curr Eye Res. 16:1997;422-427.
55. Goldaracena M.B., Pastor J.C., Saornil M.A.et al. Creación de un modelo eficaz de VRP. Arch Soc Esp Oftalmol. 67:1994;127-134.
56. Goldaracena M.B., Piñon R., García A.et al. Efecto de la inyección intravítrea de factores plaquetarios asociados a la crioaplicación y su relación con la VRP. Arch Soc Esp Oftalmol (Invest). 3:1990;161-168.
57. Gonvers M. Temporary silicone oil tamponade in the management of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 100:1985;239-245.
58. Gremillion C., Peyman G., Liu K., Naguib K. Fluorosilicone oil in the treatment of retinal detachment. Br J Ophthalmol. 74:1990;643-646.
59. Grisanti S., Heimann K., Wiedemann P. Immune response to specific molecules of the retina in proliferative vitreoretinal disorders. Graefes Arch Clin Exp Ophthalmol. 232:1994;302-307.
60. Grisanti S., Heimann K., Wiedemann P. Origin of fibronectin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy. Br J Ophthalmol. 77:1993;238-242.
61. Guerra A., Manzanas L., Giraldo A.et al. Resultados de las inyecciones de SF6 como tratamiento del desprendimiento de retina. Arch Soc Esp Oftalmol. 53:1987;393-398.
62. Hanneken A., Baird A. Soluble forms of the high-affinity fibroblast growth factor receptor in human vitreous fluid. Invest Ophthalmol Vis Sci. 36:1995;1192-1196.
63. Hart P.H., Vitti G.F., Burgess D.R.et al. Potential antiinflammatory effects of interleukin 4. Suppression of human monocyte tumor necrosis factor-β, interleukin-1, and prostaglandin-E2 Proc Natl Acad Sci U S A. 86:1989;3803-3807.
64. Haut J., Seigle P., Larricart P.et al. Circular subtotal retinectomy and inferior semicircular retinotomy. Preliminary report Ophthalmologica. 191:1985;65-74.
65. Hermsen L.M., Fulcher S.F., Soiekerman A.M.et al. Long-term inhibition of cellular proliferation by immunotoxins. Arch Ophthalmol. 198:1990;1009-1011.
66. Hernaez C., Saornil M.A., Pastor J.C.et al. Estudio experimental de la vitreorretinopatía proliferante. Comparación entre dos modelos. Arch Soc Esp Oftalmol. 58:1990;233-242.
67. Hiscot P.S., Grierson I., McLeod D. Retinal pigment epithelial cells in epiretinal membranes. An immunohistochemical study Br J Ophthalmol. 68:1984;708-715.
68. Immonen I., Tervo K., Virtanen I.et al. Immunohistochemical demonstration of cellular fibronectin and tenascin in human epiretinal membranes. Acta Ophthalmol. 69:1991;466-471.
69. Iverson D.A., Katsura H., Hartzer M.K., Blumenkranz M.S. Inhibition of intraocular fibrin formation following infusion of low-molecular-weight heparin during vitrectomy. Arch Ophthalmol. 109:1991;405-409.
70. Iverson D.A., Ward T.G., Blumenkranz M.S. Indications and results of relaxing retinotomy. Ophthalmology. 97:1990;1298-1304.
71. Johnson R., Blankenship G. A prospective, randomized, clinical trial of heparin therapy for postoperative intraocular fibrin. Ophthalmology. 95:1988;312-317.
72. Johnston R. Immunology. Monocytes and macrophages N Engl J Med. 318:1988;747-752.
73. Koerner F., Merz A., Gloor B., Wagner E. Postoperative retinal fibrosis - a controlled clinical study of systemic steroid therapy. Graefes Arch Clin Exp Ophthalmol. 219:1982;268-271.
74. Kono T., Kohno T., Inomata H. Epiretinal membrane formation. Light and electron microscopic study in an experimental rabbit model. Arch Ophthalmol. 113:1995;359-363.
75. Kuratsu J., Ushio Y. Antiproliferative effect of trapidil, a platelet-derived growth factor antagonist, on a glioma cell line in vitro. J Neurosurg. 73:1990;436-440.
76. Kuriyama S., Ohuchi T., Yoshimura N.et al. Evaluation of radiation therapy for experimental proliferative vitreoretinopathy in rabbits. Graefes Arch Clin Exp Ophthalmol. 228:1990;552-555.
77. Lazarus H.S., Russell S.R., Zahn S., Hageman G.S. Histochemical evidence for vitreous hyalocytes as components of pathological vitreous membranes (abstract). Invest Ophthalmol Vis Sci. 33(Suppl):1992;58.
78. Lean J.S., Stern W.H., Irvine A., Azen S.P. The Silicone Study Group. Classification of proliferative vitreoretinopathy used in the Silicone Study. Ophthalmology. 96:1989;756-771.
79. Ligget P.E., Skolik S.A., Horio B.et al. Human autologous serum for the treatment of full-thickness macular holes. Ophthalmology. 102:1995;1071-1076.
80. Limb G.A., Little B.C., Meager A.et al. Cytokines in proliferative vitreoretinopathy. Eye. 5:1991;686-693.
81. López M.I., Alonso I., Saornil M.A.et al. Análisis experimental de la reacción inflamatoria provocada por las siliconas fluoradas a nivel intraocular. Arch Soc Esp Oftalmol (invest). 2:1989;149-154.
82. Lopez R., Chang S. Long-term results of vitrectomy and perfluorocarbon gas for the treatment of severe proliferative vitreoretinopathy. Am J Ophthalmol. 113:1992;424-428.
83. Lucke K.H., Föester M.H., Laqua H. Long-term results of vitrectomy and silicone oil in 500 cases of complicated retinal detachments. Am J Ophthalmol. 104:1987;624-633.
84. Lucke K.H., Laqua H. Silicone Oil in the Treatment of Complicated Retinal Detachments. 1990;Springer-Verlag, Berlin.
85. Machemer R. Retinotomy. Am J Ophthalmol. 92:1981;768-774.
86. Machemer R. Pathogenesis and classification of massive periretinal proliferation. Br J Ophthalmol. 62:1978;737-747.
87. Machemer R., Aaberg T.M., Freeman M.et al. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 112:1991;159-165.
88. Madelcon M.S., Machemer R., Fineberg E., Hersch S.B. Proliferation and metaplasia of intravitreal retinal pigment epithelium cell autotransplants. Am J Ophthalmol. 80:1975;227-237.
89. Martini B. Proliferative vitreo-retinal disorders. Experimental models in vivo and in vitro Acta Ophthalmol. 201(Suppl):1992;1-63.
90. McCuen B.W., De Juan E., Landers M.B.et al. Silicone oil in vitreoretinal surgery. II. Results and complications Retina. 5:1985;198-205.
91. McCuen B.W., Hida T., Sheta S.M. Transvitreal cyanoacrylate retinopexy in the management of complicated retinal detachment. Am J Ophthalmol. 104:1987;127-132.
92. Michels R., Wilkinson C., Rice T.A. Retinal Detachment. 1990;CV Mosby, St Louis.
93. Mietz H., Heimann K. Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal diseases. Br J Ophthalmol. 79:1995;874-877.
94. Mietz H., Walshe R., Widemann P.et al. Histopathologic study of epiretinal proliferations after vitrectomy with daunomycin and silicone oil. Retina. 14:1994;425-429.
95. Miller B., Miller H., Patterson R., Ryan S.J. Retinal wound healing. Cellular activity at the vitreoretinal interface. Arch Ophthalmol. 104:1986;281-285.
96. Miyamoto K., Refojo M.F., Tolentino F.I.et al. Fluorinated oils as experimental vitreous substitutes. Arch Ophthalmol. 104:1986;1053-1056.
97. Nomoto A., Mutoh S., Hagihara H., Yamaguchi I. Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nilvadipine. Atherosclerosis. 72:1988;213-219.
98. Ohsato M., Shiga S., Kato H.et al. Immunohistochemical study of cellular fibronectin in preretinal membranes. Retina. 14:1994;430-434.
99. Ohuchi T., Kuriyama S., Yoshimura N.et al. Suppression of human retinal pigment epithelial cell proliferation by hyperthermia. Arch Ophthalmol. 108:1990;873-875.
100. Olesza E.L. Inhibition of mitogenic activity of PDGF, EGF and FGF by interferon gamma. Exp Cell Res. 179:1988;575-580.
101. Pastor J.C., López M.I., Saornil M.A.et al. Intravitreal silicone and fluorosilicone oils. Pathologic findings in rabbit eyes Acta Ophthalmol. 70:1992;651-658.
102. Peyman G.A., Shulman J.A. Vitreous Substitutes. 1995;Appleton and Lange, East Norwalk.
103. Piñon R., Pastor J.C., Saornil M.A.et al. Intravitreal and subretinal proliferation induced by platelet-rich plasma injection in rabbits. Curr Eye Res. 11:1992;1047-1055.
104. Piñon R., Pastor J.C., Saornil M.A.et al. Estudio experimental del efecto de la inyección intravítrea de plasma rico en plaquetas asociada a crioaplicación y vitrectomía. Arch Soc Esp Oftalmol. 63:1991;313-320.
105. Piñon R., Saornil M.A., Goldaracena M.B.et al. Estudio experimental del efecto de la inyección intravítrea del plasma rico en plaquetas. Resultados preliminares. Arch Soc Esp Oftalmol. 57:1989;555-564.
106. Raymond L., Jacobson B. Isolation and identification of stimulatory and inhibitory cell growth factors in bovine vitreous. Exp Eye Res. 34:1982;267-286.
107. The Retina Society Terminology Committee The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 90:1983;121-125.
108. Ryan S.J. Traction retinal detachment. XLIX Edward Jackson Memorial Lecture. Am J Ophthalmol. 115:1993;1-20.
109. Ryan S.J. The pathophysiology of proliferative vitreoretinopathy and its management. Am J Ophthalmol. 100:1985;188-193.
110. Scheiffarth O.F., Kampik A., Gunther-Koszka H., Von der Mark K. Collagens, fibronectin and laminin in proliferative vitreoretinopathy. Heimann K., Wiedemann P. Proliferative Vitreoretinopathy. 1989;134-138 Kaden, Heidelberg.
111. Schultz G.S., Grant M.B. Neovascular growth factors. Eye. 5:1991;170-180.
112. Scott J.D. Pathogenesis of PVR with analysis of events leading to recurrent retinal detachment. Heimann K., Wiedemann P. Proliferative Vitreoretinopathy. 1989;150-153 Kaden, Heidelberg.
113. Sebag J., Tang M. Pneumatic retinopexy using only air. Retina. 13:1993;8-12.
114. The Silicone Study Group Postoperative intraocular pressure abnormalities in the Silicone Study. Silicone Study Report 4. Ophthalmology. 100:1993;1629-1635.
115. The Silicone Study Group: Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy. Silicone Study Report 3. Retina 13:279-284, 1993.
116. The Silicone Study Group: Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: Results of a randomized clinical trial. Silicone Study Report 2. Arch Ophthalmol 110:780-792, 1992.
117. The Silicone Study Group: Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: Results of a randomized clinical trial. Silicone Study Report 1. Arch Ophthalmol 110:770-779, 1992.
118. Smiddy W.E., Glaser B.M., Green W.R.et al. Transforming growth factor beta. A biologic chorioretinal glue. Arch Ophthalmol. 107:1989;577-680.
119. Smith L.E.H., Aiello L.P., Foley E.D.et al. Inhibition of proliferative retinopathy using antisense phosphorothioate olignucleotides against vascular endothelial growth factor (VEGF/VPF) (abstract). Invest Ophthalmol Vis Sci. 36(Suppl):1995;S871.
120. Souza O.F., Sakamoto T., Kimura H.et al. Inhibition of experimental proliferative vitreoretinopathy in rabbits by suramin. Ophthalmologica. 209:1995;211-216.
121. Steinhorst U., Chen E.P., Hatchell D.L.et al. Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 34:1993;1753-1760.
122. Steinhorst U., Chen E.P., Machemer R., Hatchell D.L. N,N-Dimethyladriamycin for treatment of experimental vitreoretinopathy. Efficacy and toxicity on the rabbit retina Exp Eye Res. 56:1993;489-495.
123. Stolba U., Binder S., Velikay M.et al. Use of perfluorocarbon liquids in proliferative vitreoretinopathy. results and complications Br J Ophthalmol. 79:1995;1106-1110.
124. Stout T., Kimura H., Sakamoto T.et al. Gene therapy for proliferative vitreoretinopathy. Exp Eye Res. 63(Suppl):1996;S12.
125. Tang S., Scheiffarth O.F., Wildner G.et al. Lymphocytes, macrophages and HLA-DR expression in vitreal and epiretinal membranes of proliferative vitreoretinopathy. An immunohistochemical study. Ger J Ophthalmol. 1:1992;176-179.
126. Tano Y., Chandler D., Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 90:1980;810-816.
127. Uram M. Laser endoscope in the management of proliferative vitreoretinopathy. Ophthalmology. 101:1994;1404-1408.
128. Velikay M., Wedrich A., Stolba U.et al. Experimental long-term vitreous replacement with purified and nonpurified perfluorodecalin. Am J Ophthalmol. 116:1993;565-570.
129. Vidauri-Leal J., Hohman R., Glaser B.M. Effect of vitreous on morphologic characteristics of retinal pigment epithelial cells. A new approach to the study of proliferative vitreoretinopathy. Arch Ophthalmol. 102:1984;1220-1223.
130. Ward T., Hartzer M., Blumenkranz M., Lin L. A comparison of 5-fluorouridine and 5-fluorouracil in an experimental model for the treatment of vitreoretinal scarring. Curr Eye Res. 12:1993;397-401.
131. Weller M., Wiedemann P., Heimann K. Proliferative vitreoretinopathy. Is it anything more than wound healing at the wrong place? Int Ophthalmol. 14:1990;105-117.
132. Wiedemann P. Growth factors in retinal diseases. proliferative vitreoretinopathy, proliferative diabetic retinopathy and retinal degeneration Surv Ophthalmol. 36:1992;373-384.
133. Wiedemann P., Evans P.Y., Widemann R.et al. A fluorescein angiographic study on patients with proliferative vitreoretinopathy treated by vitrectomy and intraocular daunomycin. Int Ophthalmol. 13:1989;211-216.
134. Wiedemann P., Leinung C., Hilgers R.D., Heimann K. Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 229:1991;150-152.
135. Wiedemann P., Weller M. The pathophysiology of proliferative vitreoretinopathy. Acta Ophthalmol. 189(Suppl):1988;3-15.
136. Wilkins R.B., Kulwin D.R. Wound healing. Ophthalmology. 86:1979;507-510.
137. Williams G.A., Lambrou F.H., Jaffe G.A.et al. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. Arch Ophthalmol. 106:1988;1055-1058.
138. Yang C.H., Cousins S. Quantitative assessment of growth stimulating activity of the vitreous during PVR. Invest Ophthalmol Vis Sci. 33:1992;2436-2442.
139. Yang C.H., Huang T.F., Liu K.R.et al. Inhibition of retinal pigment epithelial cell-induced tractional detachment by disintegrins, a group of Arg-Gly-Asp-containing peptides from viper venom. Invest Ophthalmol Vis Sci. 37:1996;843-854.